Back to Search
Start Over
Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations.
- Source :
-
Future oncology (London, England) [Future Oncol] 2021 Feb; Vol. 17 (5), pp. 517-527. Date of Electronic Publication: 2020 Oct 06. - Publication Year :
- 2021
-
Abstract
- Aim: Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice. Patients & methods: Management plans for 112 consecutively tested patients with stage I-III melanoma were evaluated for duration and number of clinical visits, blood work and imaging. Results: 31-GEP high-risk (class 2; n = 46) patients received increased management compared with low-risk (class 1; n = 66) patients. Test results were most closely associated with follow-up and imaging. Of class 1 patients, 65% received surveillance intensity within guidelines for stage I-IIA patients; 98% of class 2 patients received surveillance intensity equal to stage IIB-IV patients. Conclusion: We suggest clinical follow-up and metastatic screening be adjusted according to 31-GEP test results.
- Subjects :
- Adult
Aged
Aged, 80 and over
Clinical Decision-Making
Female
Follow-Up Studies
Gene Expression Profiling
Humans
Male
Melanoma genetics
Melanoma secondary
Melanoma therapy
Middle Aged
Neoplasm Staging standards
Prognosis
Prospective Studies
Retrospective Studies
Skin Neoplasms genetics
Skin Neoplasms pathology
Skin Neoplasms therapy
United States
Watchful Waiting standards
Biomarkers, Tumor genetics
Melanoma diagnosis
Practice Guidelines as Topic
Skin Neoplasms diagnosis
Surgical Oncology standards
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8301
- Volume :
- 17
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Future oncology (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 33021104
- Full Text :
- https://doi.org/10.2217/fon-2020-0827